SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial.
Cristina Garcia-BeltranRita MalpiqueMarianne S AndersenFirdevs BasJudit BassolsFeyza DarendelilerMarta DíazBarbara DierisFlaminia FanelliElke Fröhlich-ReitererAlessandra GambineriDorte GlintborgAbel López-BermejoChristopher MannSilvia MarinBarbara Obermayer-PietschRønnaug ØdegårdPernille RavnThomas ReinehrMatteo RenzulliCristina SalvadorViola SingerEszter VankyJuan Vicente TorresMelek YildizFrancis de ZegherLourdes IbañezPublished in: Trials (2023)
EudraCT 2021-003177-58. Registered on 22 December 2021. https://www.clinicaltrialsregister.eu/ctr-search/search?query=%092021-003177-58 .